NASDAQ:APTO - Aptose Biosciences Stock Price, Forecast & News

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. View Aptose Biosciences' Earnings History.

Aptose Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Aptose Biosciences.

6 Wall Street analysts have issued 12 month price objectives for Aptose Biosciences' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Aptose Biosciences' stock price to reach $6.80 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for Aptose Biosciences.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptose Biosciences.

Media coverage about APTO stock has been trending positive this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptose Biosciences earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Aptose Biosciences.

Aptose Biosciences saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 310,000 shares, a decrease of 32.2% from the December 15th total of 457,200 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.5% of the company's shares are short sold. View Aptose Biosciences' Current Options Chain.

Some companies that are related to Aptose Biosciences include Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Alector (ALEC), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO), Mesoblast (MESO), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS) and AVITA MED LTD/S (RCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Canopy Growth (CGC), Micron Technology (MU), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Corbus Pharmaceuticals (CRBP).

Aptose Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.32%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View Institutional Ownership Trends for Aptose Biosciences.

APTO stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for Aptose Biosciences.

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APTO stock can currently be purchased for approximately $5.88.

Aptose Biosciences has a market capitalization of $447.53 million. The biotechnology company earns $-28,870,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. View Additional Information About Aptose Biosciences.

The official website for Aptose Biosciences is http://www.aptose.com/.

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]